Endobronchial Ultrasound Biopsy Global Market Report 2026

Endobronchial ultrasound biopsy is a minimally invasive medical procedure that utilizes a bronchoscope fitted with an integrated ultrasound probe to view structures inside and surrounding the airways. It provides real-time imaging guidance to obtain tissue samples from chest lymph nodes or masses for diagnostic evaluation. This technique improves the precision of diagnosing lung conditions and mediastinal abnormalities while reducing the requirement for more invasive surgical procedures.

The primary procedure types of endobronchial ultrasound biopsy include convex probe endobronchial ultrasound guided biopsy and radial probe endobronchial ultrasound guided biopsy. Convex probe endobronchial ultrasound guided biopsy refers to a minimally invasive procedure that utilizes a convex ultrasound bronchoscope to obtain real-time guided tissue samples from lymph nodes and lung lesions. The different product types include endobronchial ultrasound scopes, biopsy needles and sampling consumables, ultrasound processors and imaging systems, and accessories and ancillary devices, and the usability types include reusable devices and single use devices. They are applied in lung cancer diagnosis and staging, granulomatous and infectious disease evaluation, and other applications, serving end users such as hospitals and specialty cancer centers, ambulatory surgical centers, and diagnostic imaging and biopsy centers.

Tariffs are influencing the endobronchial ultrasound biopsy market by raising the cost of imported bronchoscopic ultrasound systems, biopsy needles, imaging processors, and disposable sampling consumables required for minimally invasive pulmonary diagnostic procedures. This is slowing equipment procurement and technology adoption across hospitals and specialty cancer centers, particularly in regions dependent on imported medical devices such as Asia-Pacific and Latin America. Hardware-intensive segments such as ultrasound imaging systems, reusable scopes, and biopsy consumables are being most impacted due to global supply chain dependencies. However, tariffs are also driving local medical device manufacturing, regional supplier diversification, and increased investment in domestic diagnostic technology ecosystems, creating long-term resilience in the market.

The endobronchial ultrasound biopsy market research report is one of a series of new reports from The Business Research Company that provides endobronchial ultrasound biopsy market statistics, including endobronchial ultrasound biopsy industry global market size, regional shares, competitors with a endobronchial ultrasound biopsy market share, detailed endobronchial ultrasound biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the endobronchial ultrasound biopsy industry. This endobronchial ultrasound biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endobronchial ultrasound biopsy market size has grown strongly in recent years. It will grow from $0.66 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of lung cancer cases, increasing adoption of minimally invasive diagnostic procedures, growth in hospital-based bronchoscopy units, advancements in ultrasound-guided biopsy technologies, expanding awareness of early thoracic disease diagnosis.

The endobronchial ultrasound biopsy market size is expected to see strong growth in the next few years. It will grow to $0.93 billion by 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing demand for precision-guided pulmonary diagnostics, growing adoption of single use biopsy devices, expansion of AI-enabled bronchoscopy imaging systems, rising investments in cancer diagnostic infrastructure, increasing utilization of outpatient and ambulatory biopsy procedures. Major trends in the forecast period include increasing adoption of minimally invasive mediastinal biopsy procedures, rising preference for single use endobronchial ultrasound devices, growing demand for real-time lymph node sampling accuracy, expansion of lung cancer screening and diagnostic programs, increasing use of advanced ultrasound-guided peripheral lung lesion localization.

The rising incidence of lung cancer is expected to propel the growth of the endobronchial ultrasound biopsy market going forward. Lung cancer is a type of malignant tumor characterized by uncontrolled and abnormal cell proliferation in lung tissues that can invade nearby structures or metastasize to distant organs. The increasing incidence of lung cancer is contributing to multiple risk factors such as higher smoking prevalence and environmental exposures that elevate the likelihood of lung malignancies. Endobronchial ultrasound biopsy is supporting precise and minimally invasive sampling of lung and mediastinal tissues, thereby enabling accurate diagnosis, staging, and monitoring of lung cancer, which further contributes to guiding targeted treatment decisions and improving patient outcomes. For instance, in March 2026, according to the Cancer Research UK (CRUK), a UK-based Cancer Research UK (CRUK), for women in the UK, the European age-standardised (AS) incidence rate of lung cancer is projected to increase by 2% between 2024-2026 and 2038-2040, rising from approximately 75.8 to 77.6 cases per 100,000 women per year. Therefore, the increasing incidence of lung cancer is propelling the growth of the endobronchial ultrasound biopsy market.

Leading companies operating in the endobronchial ultrasound biopsy market are focusing on developing innovative products such as next-generation EBUS bronchoscopes to enhance diagnostic accuracy and improve minimally invasive lung cancer procedures. Next-generation EBUS bronchoscopes are advanced endoscopic devices with integrated high-resolution ultrasound probes that allow real-time imaging of airways and lymph nodes, helping clinicians perform more precise, minimally invasive lung biopsies compared to traditional bronchoscopes. For example, in September 2025, Olympus Corporation, a Japan-based medical technology company, launched the BF-UC190F EBUS bronchoscope, an innovative device designed to improve diagnostic accuracy and procedural efficiency in thoracic oncology. The BF-UC190F features a thinner, more flexible insertion tube, a high-resolution ultrasound probe, and enhanced maneuverability, enabling clinicians to access difficult-to-reach lymph nodes while reducing patient discomfort. Its ergonomic design and improved imaging capabilities support safer, faster biopsies and reduce the need for repeat procedures. This advanced bronchoscope is particularly beneficial in early lung cancer detection and staging, offering real-time guidance for needle aspiration and tissue sampling.

In February 2025, Micro-Tech (Nanjing) Co. Ltd., a China-based healthcare technology company, acquired Creo Medical S. L. U. (CME) for an undisclosed amount. With this acquisition, Micro-Tech (Nanjing) Co., Ltd. aims to expand its global footprint and strengthen its distribution network across Europe by leveraging CME's established sales channels and complementary product portfolio. Creo Medical S. L. U. (CME) is a Spain-based healthcare technology company specializing in endobronchial ultrasound biopsy solutions.

Major companies operating in the endobronchial ultrasound biopsy market are Medtronic plc, Siemens Healthcare Private Limited, FUJIFILM Holdings Corporation, Koninklijke Philips N. V., GE HealthCare Technologies Inc., Boston Scientific Corporation, Konica Minolta Inc., Intuitive Surgical Inc., Olympus Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., STERIS plc, Teleflex Incorporated, Canon Medical Systems Corporation, Cook Group Incorporated, CONMED Corporation, PENTAX Medical, Esaote S. p. A., Medi-Globe Technologies GmbH, ENDO-FLEX GmbH, Taewoong Medical Co. Ltd., ACE Medical Devices Private Limited, Body Vision Medical Ltd., Clinodevice S. r. l.

North America was the largest region in the endobronchial ultrasound biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endobronchial ultrasound biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the endobronchial ultrasound biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endobronchial ultrasound biopsy market consists of revenues earned by entities by providing services such as diagnostic tissue sampling, lymph node staging, real-time ultrasound imaging, procedure planning and guidance, and post-procedural analysis and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The endobronchial ultrasound biopsy market also includes sales of needle adapters, ultrasound processors, light sources, video processors, monitor systems, guide sheaths, disposable biopsy forceps, and cytology brushes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endobronchial Ultrasound Biopsy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses endobronchial ultrasound biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endobronchial ultrasound biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The endobronchial ultrasound biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Procedure Type: Convex Probe Endobronchial Ultrasound Guided Biopsy; Radial Probe Endobronchial Ultrasound Guided Biopsy
• 2) By Product Type: Endobronchial Ultrasound Scopes; Biopsy Needles And Sampling Consumables; Ultrasound Processors And Imaging Systems; Accessories And Ancillary Devices
• 3) By Usability: Reusable Devices; Single Use Devices
• 4) By Application: Lung Cancer Diagnosis And Staging; Granulomatous And Infectious Disease Evaluation; Other Applications
• 5) By End User: Hospitals And Specialty Cancer Centers; Ambulatory Surgical Centers; Diagnostic Imaging And Biopsy Centers
• Subsegments:
• 1) By Convex Probe Endobronchial Ultrasound Guided Biopsy: Transbronchial Needle Aspiration Guided Procedures; Real Time Lymph Node Sampling Procedures; Mediastinal Staging Biopsy Procedures; Central Lung Lesion Biopsy Procedures; Combined Bronchoscopic Ultrasound Guided Sampling Procedures
• 2) By Radial Probe Endobronchial Ultrasound Guided Biopsy: Peripheral Lung Lesion Localization Procedures; Guide Sheath Assisted Biopsy Procedures; Transbronchial Forceps Biopsy Procedures; Brush Cytology Sampling Procedures; Fluoroscopy Assisted Peripheral Biopsy Procedures
• Companies Mentioned: Medtronic plc; Siemens Healthcare Private Limited; FUJIFILM Holdings Corporation; Koninklijke Philips N.V.; GE HealthCare Technologies Inc.; Boston Scientific Corporation; Konica Minolta Inc.; Intuitive Surgical Inc.; Olympus Corporation; Shenzhen Mindray Bio-Medical Electronics Co. Ltd.; STERIS plc; Teleflex Incorporated; Canon Medical Systems Corporation; Cook Group Incorporated; CONMED Corporation; PENTAX Medical; Esaote S.p.A.; Medi-Globe Technologies GmbH; ENDO-FLEX GmbH; Taewoong Medical Co. Ltd.; ACE Medical Devices Private Limited; Body Vision Medical Ltd.; Clinodevice S.r.l.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.